The NY Times reports that a federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property.
U.S. Judge Invalidates Human Gene Patent
2 Comments
Recent Posts
Why the Verdict on Social Media Defective Design Harming Children Gets the Instinct Right But the Law Wrong 
Scoping in the Tech Giants: Bill C-22’s International Production Order and the Shift to a Less Privacy-Protective Cross-Border Disclosure System 
The Law Bytes Podcast, Episode 263: The Lawful Access Act Roundtable With David Fraser and Robert Diab 
When Writing About Antisemitism Proves the Point: What the Replies Reveal 
Acting on Antisemitism: If This Was Always Possible, Why Didn’t It Happen Sooner?
“Myriad Genetics, the company that holds the patents with the University of Utah Research Foundation, asked the court to dismiss the case, claiming that the work of isolating the DNA from the body transforms it and makes it patentable. ”
So, they claim they aren’t actually patenting the two genes, they are patenting transformed version of the genes? To me this would invalidate the work of the human genome project, as they cataloged not the human genome but some variation thereof… Or am I understanding the claim incorrectly?
They’re claiming that isolated DNA is “transformed”, so the not-found-in-nature requirement of a patent doesn’t apply to the genes.